Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;19(1):37-42.
doi: 10.7861/clinmedicine.19-1-37.

Calorie restriction for long-term remission of type 2 diabetes

Affiliations
Review

Calorie restriction for long-term remission of type 2 diabetes

Roy Taylor. Clin Med (Lond). 2019 Jan.

Erratum in

Abstract

Starting with a hypothesis which postulated a simple explanation arising from the basic cause of type 2 diabetes, a series of studies has introduced a paradigm shift in our understanding of the condition. Gradual accumulation of fat in the liver and pancreas leads eventually to beta cell dedifferentiation and loss of specialised function. The consequent hyperglycaemia can be returned to normal by removing the excess fat from liver and pancreas. At present this can be achieved only by substantial weight loss, and a simple practical and efficacious method for this has been developed and applied in a series of studies. For those people who used to have type 2 diabetes, the state of post-diabetes can be long term provided that weight regain is avoided. The implications for personal health and for national health economics are considerable.

Keywords: Type 2 diabetes; first phase insulin response; liver fat; pancreas fat; reversal of type 2 diabetes.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
The twin cycle hypothesis: during long-term intake of more calories than are expended each day, excess carbohydrate must undergo de novo lipogenesis, which particularly promotes fat accumulation in the liver. As insulin stimulates de novo lipogenesis, people with insulin resistance (determined by family or lifestyle factors) will accumulate liver fat more readily than others due to the higher plasma insulin levels. The increased liver fat will cause relative resistance to insulin-suppression of hepatic glucose production. Over many years a modest increase in fasting plasma glucose level will cause increased basal insulin secretion rates as a homeostatic response. The consequent hyperinsulinemia will increase further the conversion of excess calories into liver fat. A vicious cycle of hyperinsulinemia and inadequate suppression of hepatic glucose production becomes established. Fatty liver leads to increased export of very low density lipoprotein (VLDL) triacylglycerol which will increase fat delivery to all tissues including the islets. Excess fatty acid availability in the pancreatic islet impairs the acute insulin secretion in response to ingested food, and at a certain level of fatty acid exposure, dedifferentiation of the beta cell will occur with post-prandial hyperglycaemia. The hyperglycaemia will further increase insulin secretion rates, with secondary increase of hepatic lipogenesis, spinning the liver cycle faster and driving on the pancreas cycle. Eventually the fatty acid and glucose inhibitory effects on the islets reach a trigger level for dedifferentiation, leading to a relatively sudden onset of clinical diabetes. Figure adapted with permission from R Taylor.
Fig 2.
Fig 2.
Data from Counterpoint showing (a) plasma glucose, (b) hepatic triglyceride content, (c) hepatic insulin sensitivity, (d) pancreas triglyceride content and (e) first phase insulin response. Data are shown as mean ±standard error, for diabetic subjects (filled circles) and measured at a single time point for a weight matched non-diabetic control group. Figures reproduced with permission from Lim et al.
Fig 3.
Fig 3.
Data from DiRECT showing (a) hepatic triglyceride, (b) total plasma triglycerides, (c) hepatic VLDL1-TG production, (d) intrapancreatic triglyceride, (e) fasting plasma VLDL1-TG and (f) fasting plasma insulin. Time points are at baseline, post weight loss (5 months), and 12 months. Responders (those achieving non-diabetic glucose control; n=40) are shown as a solid line, and non-responders (those remaining in the diabetic range of HbA1c or plasma glucose) as a dotted mid green line. Those randomised to control (continuation of best practice by current guidelines) are shown as a dotted light green line. Figure reproduced with permission from Taylor et al. **p<0.01 vs. baseline, ***p<0.0001 vs. baseline (responders) ††p<0.01 vs. baseline, †††p<0.0001 vs. baseline (non-responders) #p<0.05 vs. 5 months (responders); ‡p<0.05 vs. 5 months (non-responders); ‡‡p<0.01 vs. 5 months (non-responders)

References

    1. UKPDS Group Effect of intensive blood-glucose control with ­metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–65. - PubMed
    1. UKPDS Group UK prospective diabetes study 16: overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249–58. - PubMed
    1. Rudenski AS, Hadden DR, Atkinson AB, et al. Natural history of ­pancreatic islet B-cell function in type 2 diabetes mellitus studied over 6 years by homeostasis model assessment. Diabet Med 1988;5:36–41. - PubMed
    1. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008;10(Suppl 4):32–42. - PubMed
    1. Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 2007;104:12587–94. - PMC - PubMed

MeSH terms